
Sharmin Ghaznavi MD
Clinical Fellow in Psychiatry, Massachusetts General Hospital
Join to view full profile
101 Nicolls RdBoston, MA 11794
Phone+1 617-726-2000
Dr. Ghaznavi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 2008 - 2012
Yale School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2012 - 2028
NY State Medical License 2025 - 2027
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Clinical Trials
Publications & Presentations
PubMed
- The relationship between shame, rumination, self-compassion, and symptoms of post-traumatic stress disorder and major depressive disorder.Sarah G Richter, Lauren H Brenner, Sharmin Ghaznavi
Journal of Affective Disorders. 2026-06-15 - Differentiating Bipolar Spectrum Disorders From Other Psychiatric Disorders With Shared Features: Strategies and Implications.Mohamed Soliman, Sharmin Ghaznavi, David Mischoulon, Theodore A Stern
The Primary Care Companion for CNS Disorders. 2026-05-12 - 4 citationsClassic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.Sharmin Ghaznavi, Sarah G Richter
Drugs. 2025-05-01
Authored Content
- Peroxisome Proliferator Activated Receptor Gamma Co-Activator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric DisordersJanuary 2018
Press Mentions
Where Psychedelic Research Goes NextAugust 11th, 2022
How Do Psychedelics Combat Anxiety and Depression? MGH Researchers Are Determined to Find OutJuly 25th, 2022
Startups Are Betting on a Psychedelic Gold RushOctober 13th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: